Subjects were randomized ( 1 : 2 : 2 : 1 ) to one of three subcutaneous secukinumab 150-mg induction regimens [ Single ( Week 0 ) , Monthly ( Weeks 0 , 4 , 8 ) , Early ( Weeks 0 , 1 , 2 , 4 ) ] or placebo .